Abstract
Dystonia is a highly prevalent movement disorder that can manifest at any time across the lifespan. An increasing number of investigations have tied this disorder to dysfunction of a broad “dystonia network” encompassing the cerebellum, thalamus, basal ganglia, and cortex. However, pinpointing how dysfunction of the various anatomic components of the network produces the wide variety of dystonia presentations across etiologies remains a difficult problem. In this review, a discussion of functional network findings in non-mendelian etiologies of dystonia is undertaken. Initially acquired etiologies of dystonia and how lesion location leads to alterations in network function are explored, first through an examination of cerebral palsy, in which early brain injury may lead to dystonic/dyskinetic forms of the movement disorder. The discussion of acquired etiologies then continues with an evaluation of the literature covering dystonia resulting from focal lesions followed by the isolated focal dystonias, both idiopathic and task dependent. Next, how the dystonia network responds to therapeutic interventions, from the “geste antagoniste” or “sensory trick” to botulinum toxin and deep brain stimulation, is covered with an eye towards finding similarities in network responses with effective treatment. Finally, an examination of how focal network disruptions in mouse models has informed our understanding of the circuits involved in dystonia is provided. Together, this article aims to offer a synthesis of the literature examining dystonia from the perspective of brain networks and it provides grounding for the perspective of dystonia as disorder of network function.
Introduction
Dystonia refers to the involuntary intermittent or sustained contraction of muscles resulting in abnormal, repetitive movements (such as tremor) or postures. Dystonia occurs in isolated muscle groups (focal), contiguous muscle groups (segmental), or in groups distributed across the body (generalized) (See videos in Table 1 for examples) [, ]. Dystonia is estimated to be the 2nd or 3rd most common movement disorder, though the true prevalence is likely underestimated due to the paucity of studies on prevalence and the exclusion of cases in which those with, for instance, mild focal or task-specific dystonia may not seek medical attention [].
TABLE 1
| Axis 1 (presentation) | Axis 2 (etiology) | |
|---|---|---|
| Patient/Supplementary Video S1 | Generalized | Cerebral Palsy |
| Patient/Supplementary Video S2 | Segmental | Acquired Brain injury |
| Patient/Supplementary Video S3 | Focal | Functional |
| Patient/Supplementary Video S4 | Generalized | Genetic |
| Patient/Supplementary Video S5 | Focal/Segmental | Genetic |
Examples of different dystonias based on Axis 1 and Axis 2 classification.
Included are videos demonstrating dystonia phenotypes based on their phenomenology (indicated in the middle column) and their etiology (indicated in the right column). All videos were obtained by Dr. Mara Hull in the Movement Disorder Clinic at Texas Children’s Hospital and consent for inclusion in research studies was obtained from the patient and/or legal guardian.
Dystonia classification schemes have varied over time [, ]. The usage of “primary” and “secondary” dystonia, which have been used in varying ways to describe dystonia arising from hereditary, neurodegenerative, acquired, and idiopathic causes has recently been revisited [, ]. Confusing the older classification scheme is its inability to distinguish the phenomenology from the etiology of the dystonia, two important aspects of the disease that may at times be at odds with one another []. In an attempt to account for the dichotomy arising from etiologic and phenomenological considerations in dystonia, a recent classification scheme based on expert consensus aligned the wide variety of dystonias along two axes []: Axis 1 classifies the clinical characteristics of the disease presentation and Axis 2 classifies known etiology. Importantly, this scheme was proposed with the understanding that the dystonia afflicting a given individual could evolve along each of these axes independently and/or in parallel as the disease evolves and/or more information about the patient’s condition is obtained.
The treatment for a given dystonia can be thought of as an independent classification consideration that can relate to either axis, being more closely related to etiology in the case of deep brain stimulation (DBS) and phenomenology in the case of botulinum neurotoxin (BoNT). In general, dystonias that were formerly classified as primary dystonias, including genetic and focal/segmental idiopathic dystonias, are more amenable to treatment [] while dystonia due to lesions or acquired injury are often more difficult to treat. The former group (previously “primary”) includes the dopa-responsive dystonias and idiopathic dystonias that are often responsive to pallidal deep brain stimulation [, ]. Treatment of dystonia is often multifactorial, first targeting reversible causes such as discontinuation of the putative offending agents, as well as consideration of disease-specific therapies. When there are no disease specific treatments available, supportive measures are used that include oral medications, botulinum neurotoxin injections, or surgical interventions such as intrathecal baclofen pump or deep brain stimulation [, –]. This review will discuss the increasingly large body of literature that exists regarding the interrogation of 1) the network dysfunction underlying dystonia and 2) how therapeutic modalities act upon those dysfunctional networks.
The genetic dystonias have been thoroughly reviewed due to their prevalence and the relative ease with which diseases with mendelian inheritance can be interrogated in the genomics era, both through clinical research and with model organisms [, ]. The present review will focus on acquired and idiopathic dystonia from the perspective of brain networks with the hopes of highlighting possible commonalities between what may seem to be disparate forms of the disease along both dystonia axes. This approach takes advantage of the network specificity derived from lesion mapping—how damage to the brain is associated with network changes—and functional brain imaging—how brain networks are operating in real time—to examine how recent advances in research have come to characterize this movement disorder as having a basis in dysfunction of a “dystonia network” [–]. The primary nodes of the dystonia network include the cerebellum, the thalamus, the basal ganglia, and sensorimotor cortical regions [–]. However, higher order associative cortical regions (as will be described below) as well as deep structures that link these regions, including the midbrain, pons, and brainstem, likely have an ancillary role in dystonia pathogenesis [, , ].
To understand how dystonia network dysfunction manifests, first we will evaluate the acquired dystonias in comparison to network function in idiopathic dystonias. Next, we will evaluate how interventions that alleviate dystonia work by correcting or modulating the dysfunctional networks. Finally, we will look at mouse models both of lesion associated dystonia and of dystonia elicited by direct network manipulation. These perspectives on dystonia etiology complement one another and we hope will offer a fresh synthesis working towards the understanding of how network dysfunction contributes to dystonia and what that tells us about broader disease etiology. We hope that this perspective will help inform therapeutic interventions in the dystonias that have remained intractable to therapy through an emphasis on understanding the neural substrates of the disease.
Acquired, lesion-associated, and isolated idiopathic focal/segmental dystonia
Acquired forms of dystonia may be placed into two broad categories, those with a structural lesion within the central nervous system (CNS) and those with no clear structural abnormalities. Dystonia resulting from structural abnormalities can further be divided into those that occur early in life and are the result of more widespread CNS damage (seen in dyskinetic/dystonic cerebral palsy; Supplementary Video S1) and those that are the result of later, focal CNS lesions (i.e., ischemic/hemorrhagic stroke; Supplementary Video S2). An interesting counterpart to the focal lesion associated dystonias are the drug induced dystonias (tardive dystonia and acute dystonic reactions) and isolated idiopathic focal/segmental dystonias, which may be thought of as focal functional network disruptions, and which will be covered in the final portion of this section. Finally, outside the scope of this discussion, but interesting from the perspective of network dysfunction is functional/psychogenic dystonia of which the etiology remains more enigmatic (Supplementary Video S3); whether functional/psychogenic dystonias share the network abnormalities of idiopathic dystonia or merely converge on Axis 1 will be an interesting problem to untangle moving forward.
Dystonic cerebral palsy
Cerebral Palsy (CP) is the most common etiology of severe motor dysfunction in childhood []. While CP has traditionally been associated with spasticity, there is an increasing awareness that individuals with CP frequently experience dystonia, even to the point that is may be present in the majority of these patients [, ]. In addition to the hypertonia and movement disorders seen in CP, a wide variety of co-morbid neurodevelopmental disabilities may also be present, including epilepsy, autism spectrum disorders, and intellectual disability, implicating pathology across distributed brain networks [–]. Furthermore, CP is not an etiologic diagnosis but one made based on the timing of the presumed central nervous system insult (pre-, peri-, neo-natal), the course of the disease (stable rather than progressive), and clinical presentation []. CP thus offers a unique opportunity to evaluate the intersection of lesion location and clinical outcome. In particular, dystonic presentations of CP present an excellent opportunity to understand the genesis of acquired forms of dystonia and their associated underpinnings in network dysfunction because there is an early, acquired insult and subsequent dystonia [].
Numerous structural brain lesions are associated with CP. Periventricular leukomalacia (PVL), which is associated with premature birth and intraventricular hemorrhage (hemorrhage of the germinal matrix along the walls of the lateral ventricles), is the radiographic abnormality most commonly seen in CP. While PVL refers specifically to the direct damage to the white matter tracts along the lateral ventricles, larger intraventricular hemorrhages [] risk the disruption of subcortical brain structures including the thalamus, basal ganglia, and cerebellum [–]. Furthermore, hypoxic ischemic encephalopathy (HIE), unconjugated hyperbilirubinemia due to kernicterus, and disruption of cerebellar development associated with birth early in the third trimester are additional acquired perinatal insults associated with CP [–]. As mentioned, the cerebellum, thalamus, basal ganglia, and sensorimotor cortex encompass the key nodes of the dystonia network [–]. As will be seen throughout this review, damage and dysfunction to various parts of this network underlies many forms of dystonia. Dystonic/dyskinetic CP is unique among the acquired dystonias in that it, as described above, often encompasses damage to various structures simultaneously (Figure 1).
FIGURE 1
Several reports have investigated how subcortical regions are affected in patients with dystonic/dyskinetic CP. To start, a population-based study in CP patients investigated imaging finding in patients with all CP subtypes (n = 213) as well as those with dystonic/dyskinetic CP (n = 15) in particular [
Indeed, more recent studies using higher level structural and functional imaging modalities have found that there is evidence of broad network abnormalities in patients with dystonic/dyskinetic CP. Ballester-Plané et al. found widespread alterations in the cortico-cortico, subcortical-cortico, and intra-subcortical white matter networks using tractography [
Qin et al. next undertook two studies using functional MRI (fMRI), which is an imaging modality that identifies increased regional brain activity using blood oxygen level dependent (BOLD) signaling during periods of directed activity (task dependent) or at rest (resting state) [
Finally, it must be noted that many individuals previously diagnosed with idiopathic dystonic or dyskinetic CP have been increasingly found to have underlying genetic abnormalities and dystonias, rather than acquired brain insults, which bears further targeted investigation [
Lesion-associated dystonia
Dystonia as a distinct movement disorder was first described in the western medical literature by Marcus Walder Schwalbe in 1908, despite many previous descriptions of conditions that doubtless would be considered dystonia today [
Recently, meta-analyses of lesion based dystonia studies have evaluated the link between structural lesions and related functional outcomes [
Further questions arise regarding how lesion related dystonia informs our understanding of functional networks and idiopathic acquired dystonias. Previous work used lesion based network mapping [
Idiopathic isolated focal dystonia
We next focus on focal dystonia without an identified genetic or structural lesion, or idiopathic isolated focal dystonia. Isolated focal dystonias are generally categorized as idiopathic dystonia (i.e., blepharospasm or some cervical dystonias) or task specific focal dystonia (i.e., writer’s cramp, laryngeal dystonia). Given the possible association with a task and the absence of anatomic disease pathology it is understandable why this class of dystonias were previously considered to be a psychiatric disorder [
A second important class of focal isolated dystonia is task specific focal dystonia and peripherally induced dystonia, of which laryngeal dystonia (previously called spasmodic dysphonia) and writer’s cramp or musician’s dystonia are the most closely studied [
Given the nature of focal isolated dystonia, especially the “overuse” in task specific focal dystonia, there has been a great deal of work exploring the pathophysiology of these dystonias using fcMRI [
Furthermore, changes in white matter integrity using diffusion weighted imaging (DWI; diffusion tensor imaging (DTI)) sequences on MRI were evaluated to delve deeper into the structural basis of the identified functional network alterations [
Clues to dystonia pathophysiology derived from therapeutic intervention
Recent work in understanding the network effects of therapeutic interventions in dystonia have furthered our understanding of dystonia pathogenesis. In contrast to the genetic, “primary” dystonias that often respond well to targeted pharmacology (e.g., dopa responsive dystonias) or deep brain stimulation (DBS) targeting the basal ganglia, acquired dystonias are often difficult to treat. However, investigations into how brain networks change after sensory tricks or effective treatments (botulinum neurotoxin injections, and conventional/unconventional sites of DBS) have contributed to our understanding of the pathophysiology and etiology of acquired and idiopathic dystonias. In this section, we will explore the literature investigating how therapeutic interventions inform our understanding of the underlying dystonia networks.
Sensory trick, or geste antagoniste
The oldest non-pharmacologic intervention in focal dystonia is the “geste antagoniste” or “sensory trick,” which was first published in the western medical literature in 1893 [
Extending these findings, Wissel et al. later confirmed the finding of electromyographic improvement of cervical dystonia with the sensory trick [
FIGURE 2

Regional brain network abnormalities associated with therapeutic interventions. Patients with dystonia non-responsive [(A), upper panel] or responsive [(A), lower panel] to sensory tricks showed differences in regional functional connectivity (A). Patients non-responsive to sensory tricks showed increased connectivity across cerebellar and cortical networks [(A), top]. Patients with dystonia responsive to sensory tricks had comparatively lower regional brain connectivity which was then further decreased with trick performance [(A), bottom left vs. right]. Trick performance also led to increased cerebellar activity [(A) bottom right] [
Botulinum neurotoxin
Injection of botulinum neurotoxin (BoNT) into dystonic muscle groups is one of the key pharmacologic interventions for dystonia, especially for focal and segmental acquired dystonias [
An alternative proposed mechanism of action posits that “deafferentation” via primary effects on gamma motor neurons and resulting secondary effect on the muscle spindle is responsible for altering sensory processing peripherally [
We will summarize two of the most recent analyses regarding central effects of BoNT that each considered many of the above-described variables. The first, by Hok et al. [
In their recent study examining idiopathic cervical dystonia, Hok et al. used resting state fcMRI to understand how BoNT administration altered central network function in those who responded to the therapy as compared to those who did not [
Another recent study, performed by O’Flynn et al., furthers this conceptual framework by tackling a similar question in laryngeal dystonia [
Though the mechanism(s) for the central effects for BoNT in dystonia remains enigmatic, direct modulation of brain networks through DBS of target sites in the central nervous system is a key therapeutic intervention in refractory dystonias and offers direct evidence for how modulation of the dystonia network leads to amelioration of the movement disorder.
Deep brain stimulation
DBS is an invasive neuromodulatory procedure involving the precisely targeted insertion of electrodes into target regions of the brain to deliver electrical current. DBS has become commonplace in the treatment of several movement disorders to include Parkinson’s disease, essential tremor, Tourette syndrome, and dystonia. Furthermore, DBS is increasingly being used in a wide range of other movement, cognitive, pain, epilepsy, and affective neurologic disorders [
In dystonia, DBS (pallidal DBS in particular) is now a critical therapeutic intervention and is a first line consideration in certain generalized and segmental dystonia such as in the case of DYT-TOR1A, DYT-KMT2B and DYT-SGCE (Supplementary Video S4) [
Meta analysis has shown that there is a durable long-term benefit to DBS in pediatric patients while also pointing out the relative poor efficacy of DBS in acquired dystonia as compared to the isolated dystonias [
Given the high efficacy of pallidal DBS for idiopathic dystonia and the previous literature covering DBS in monogenic dystonias [
Given the difficulty in treatment of acquired dystonia with either GPi, subthalamic, thalamic, or combinatorial DBS approaches, alternative sites of stimulation have been considered, fore among them nodes in the cerebellar network [
In terms of DBS mechanism of action, or at least relating to its effects on brain networks, the focus will turn towards two published studies examining how activity in the dystonia network was altered with use of DBS. In the first study, 15 patients with cervical dystonia and clinical response to DBS were evaluated using fMRI [
As genetic testing may offer prognostication about efficacy in the hereditary dystonias, so one can imagine clinically directed fMRI being a useful pre-surgical evaluation in acquired dystonias; while the groundwork for such a heuristic has been laid, more research in understanding interindividual differences and how networks respond to DBS will be necessary. Furthermore, as there is often significant functional impairment in these patients, acquisition of fMRI data would be complicated by possible requirement of adjunctive sedatives during imaging and absence of task dependent fMRI data.
Together the summarized perspectives from human studies of acquired and idiopathic dystonia reveal the emergence of a dystonia network that is involved across etiologies of the disease. Furthermore, whether the etiology of the dystonia emerges from neonatal injury, focal lesions in later life, or functional aberrations in networks--and whether the alleviation of symptoms results from the geste antagoniste, botulinum neurotoxin, or DBS--the brain networks involved in dystonia seem to converge on a shared dystonia network involving the striatum, thalamus, and cerebellum and the various cortical networks involved in sensorimotor processing and integration. Next, a more fine-grained examination of these network manipulations will be taken through investigation of the literature looking at network and lesion-based dystonia models in rodents.
Rodent models of functional and acquired dystonia
Current animal models of dystonia aim to 1) model the functional network disruptions arising from the various etiologies of dystonia that are seen in humans or 2) test whether and how experimental manipulation of the networks implicated in dystonia produce the movement disorder. However, understanding how broad, non-specific alterations in a network lead to dystonia becomes difficult in the case of task dependent dystonia, genetic dystonia (where the implicated gene is often widely expressed in the brain), and dystonia resulting from non-focal lesions (as in the case of dystonic CP). As a result, the use of focal, inducible lesions in mouse models is an especially useful emerging approach to begin answering how focal network disruptions lead to dystonia.
Mouse models of non-mendelian acquired dystonia often use paradigms involving pharmacologic network manipulation. Two of the most common pharmacological dystonia-inducing agents are the excitatory glutamate agonist kainite and selective sodium channel blocker ouabain, which have been shown to induce a range of dystonic phenotypes in mice (Figure 3) [
FIGURE 3

Dystonia arising from focal manipulations in the mouse. Using examples from the indicated publications, examples of dystonia are shown arising from 1) oubain injection (blue) in the basal ganglia and cerebellar vermis [
The use of pharmacological manipulations in mice has several distinct advantages. The selective induction of dystonia by blocking specific chemical receptors or pathways has allowed researchers to uncover several promising mechanistic pathways that could prove useful in the development of treatments for dystonia. For example, the exploration of the selective GABAergic transport inhibitor drug tiagabine was first tested in adult rats with a kainic acid-induced dystonia [
Perhaps more importantly, pharmacologically induced dystonia models have been used to target specific anatomical structures in their investigation into dystonia. Using pharmacological lesions, rodent work has managed to elucidate key signaling biomarkers and mechanistic hallmarks of various dystonias in the cerebellum and basal ganglia [
As the study of lesion-acquired dystonia in mouse models continues, there are several key factors to keep in mind. Researchers attempting to classify irregular motor behavior or changes in locomotion as the result of lesion-acquired dystonia should be as specific as possible when assessing 1) what manipulations were used; 2) how the manipulation might impact multiple areas of the brain with particular attention to the network level changes involved; and 3) what the assays they are using to evaluate symptoms of dystonia are truly assessing. For example, the use of pharmacological lesions to induce dystonia may not necessarily be the most representative method when modeling dystonias associated with traumatic brain injury (TBI) or damage resulting from central nervous system pathologies such as stroke, multiple sclerosis, or cerebral palsy. In these cases, a viable alternative in mouse models may be direct electrical stimulation to disrupt normal signaling processes as described in Raike et al., where a combination of conditional genetic and electrical stimulation was used to produce dystonia in proportion to the amount cerebellar dysfunction induced [
Dystonia network manipulations in mice
In addition to the work mentioned above, which focused on understanding the impact of manipulations of key cell types, brain regions, and pathways in the broader dystonia network, work in mouse models focusing on precise manipulations of the structures and circuits associated with dystonia have allowed us to better understand how dysfunctions within a broad dystonia network may develop. White and Sillitoe focused on investigating how functional disruption of projections from the inferior olive to the cerebellum contribute to dystonia (Figure 3) [
Further investigation of cerebellar circuitry by Van der Heijden et al. [
The intersectional genetic models that cause functional lesions can further provide insight into the etiologies of symptoms that are often comorbid with dystonia [
Again, using the targeted genetic approaches available in rodent models, a synthetic approach to model and treat “acquired” etiologies of dystonia is here given a proof of principle. These data may further add weight to diversifying the targets for interventions in the difficult to treat realm of acquired dystonias. Continuing to focus on 1) how the combinations of various anatomical changes to the structures underlying a broad dystonia network result in the different features of various dystonias and 2) how these translated behaviors can be abolished or mediated by therapeutic responses could reveal the causative mechanisms and or risk factors in human dystonias and their related conditions.
Discussion
Recent efforts to characterize the dystonia network based on etiology, phenomenology, therapeutic intervention, and animal modelling have yielded a great deal of insight into the nodes that comprise the dystonia network and how they respond to insult and intervention. The most severe of the described dystonias, dystonic CP, often involves simultaneous pathology to multiple structures of the dystonia network due to the susceptibility of the immature brain to the various environmental insults present during neonatal life. By contrast, focal lesions into adulthood have a more predictable phenomenological presentation as described by Corp et al. and depicted in Figure 1, [
Functional imaging of therapeutic interventions has offered considerable insight into how the dystonia network can be modulated to alleviate the symptoms of the disease. A consistent thread across modalities is altered cerebellar activity, with both effective sensory trick and efficacious DBS resulting in increased cerebellar activity. In addition, decreased functional connectivity between the cerebellum and the cortex is seen in both successful BoNT therapy as well as in patients who have dystonia responsive to sensory tricks. Together, the anatomic and functional findings made when studying varying etiologies and treatment modalities both confirm the anatomic and functional substrates of dystonia and make it increasingly clear that more work needs to be done in understanding the precise role of each of the nodes in generating the dystonic phenotype; for instance how do the observations of increased cerebellar activity in response to therapy and the decreased functional connectivity between the cerebellum and cortex relate to one another? Can the cerebellum play a role in plastic network function, being involved in both the genesis and resolution of the movement disorder? Even with the wide and increasing breadth of literature covering dystonia, more work needs to be done to understand how these crucial brain areas work to buttress each other in both health and disease.
Rodent models are perhaps an ideal starting point for these investigations. As described, rodent models have the unique benefit of allowing targeted network manipulations in the mammalian nervous system. The genetic toolkit available in murine genetics has revealed dystonia arising from the functional manipulation of projections from single populations of neurons, which should serve as a proof of principle for ongoing studies in understanding the necessity and sufficiency different nodes in the dystonia network to produce the disorder. Furthermore, combinatorial pharmacologic neuromodulation, as described above, has made inroads towards understanding how different nodes can modulate one another.
Concluding thoughts
From the heart-rending sight of a child in the midst of a dystonic crisis to the loss of livelihood suffered by a vocalist with laryngeal dystonia, the impact of this enigmatic and unfortunately prevalent disorder can be difficult to overstate. Dystonia can be a co-morbid movement disorder that compounds and exacerbates the complex needs of children with severe neurodevelopmental disability; it can manifest as a provoked attack in children with CP, causing anxiety and robbing joy from moments of celebration; for adults it can disrupt basic activities of life: blepharospasm causing one’s loss of independence through an inability to drive; task specific focal dystonia ending a promising career. However, progress towards understanding the network basis of dystonia is being made through the concerted effort of an expanding field of researchers. The increasing consensus implicating dysfunction in a broad dystonia network across many etiologies of this disorder should help to sculpt therapeutic modalities toward targeted interventions.
Furthermore, while mentioned only briefly in the review, there is an increasing awareness that dystonia, though presented and conceptualized as a movement disorder, may involve many non-motor domains and lead to emotional, autonomic, cognitive, and sleep disorders [
Statements
Ethics statement
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments. Informed consent was obtained from all patients for being included in the study. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.
Author contributions
JG and RS conceived of the review concept and scope; MN conceived of and composed the figures; MH obtained patient videos, consent from patients, and performed the examinations; JG, MvH, and KN contributed to rodent dystonia section; JG, MH, MvH, ST, and RS revised the manuscript, MH and ST provided input on current practice in dystonia management. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by Baylor College of Medicine (BCM), Texas Children’s Hospital, The Hamill Foundation, and the National Institutes of Neurological Disorders and Stroke (NINDS) R01NS100874, R01NS119301, and R01NS127435 to RS. Research reported in this publication was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number P50HD103555 for use of the Cell and Tissue Pathogenesis Core and In Situ Hybridization Core (the BCM IDDRC). MvH was supported by K99NS130463. JG was supported by NIH-NINDS K08NS121600.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Author disclaimer
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontierspartnerships.org/articles/10.3389/dyst.2023.11805/full#supplementary-material.
SUPPLEMENTARY VIDEO S1Generalized dystonia in dystonic/dyskinetic cerebral palsy: Apparent is severe axiadystonia with opisthotonic posturing, retrocollis, torticollis, and oromandibular dystonia. Also present are stereotypies of the upper extremities.
SUPPLEMENTARY VIDEO S2Hemidystonia due to tuberculous meningitis: This patient has left sided appendicular dystonia resulting from an acquired brain injury. Evident is dystonic posturing of the left hand, arm, leg, and foot. Dystonia worsens with action, in particular walking, while walking backwards there is slight improvement in gait.
SUPPLEMENTARY VIDEO S3Functional focal dystonia. This patient has focal, fixed, right foot inversion and inward rotation of at the hip with acute onset. There is no fluctuation of the dystonia and when the patient turns with walking the foot returns to normal position briefly and then the fixed position. The findings are consistent with a pure functional dystonia.
SUPPLEMENTARY VIDEO S4Generalized Tor1A dystonia responsive to GPi DBS. Pre-DBS video shows a generalized dystonia with severe restriction of movement with significant pain. Post-DBS the patient has achieved significant improvement in motor function as is evident through the comparative examination as well as the gait performance.
SUPPLEMENTARY VIDEO S5Segmental Thap1 dystonia. This genetic dystonia can cause focal/segmental dystonia which is evident in the patient’s cervical dystonia (laterocollis and torticollis), oromandibular dystonia, toe extension dystonia, and voice abnormality (laryngeal dystonia).
References
1.
AlbaneseABhatiaKBressmanSBDelongMRFahnSFungVSCet alPhenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 28(7):863–73. 10.1002/mds.25475
2.
BalintBMencacciNEValenteEMPisaniARothwellJJankovicJet alDystonia. Nat Rev Dis Prim (2018) 4(1):25. 10.1038/s41572-018-0023-6
3.
DefazioG. The epidemiology of primary dystonia: current evidence and perspectives. Eur J Neurol (2010) 17(1):9–14. 10.1111/j.1468-1331.2010.03053.x
4.
Di BiaseLDi SantoACaminitiMLPecoraroPMDi LazzaroV. Classification of dystonia. Life (2022) 12(2):206. 10.3390/life12020206
5.
BrownEGBledsoeIOLuthraNSMiocinovicSStarrPAOstremJL. Cerebellar deep brain stimulation for acquired hemidystonia. Mov Disord Clin Pract (2020) 7(2):188–93. 10.1002/mdc3.12876
6.
WijemanneSJankovicJ. Dopa-responsive dystonia - clinical and genetic heterogeneity. Nat Rev Neurol (2015) 11(7):414–24. 10.1038/nrneurol.2015.86
7.
MoroELeReunCKraussJKAlbaneseALinJPWalleser AutieroSet alEfficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis. Eur J Neurol (2017) 24(4):552–60. 10.1111/ene.13255
8.
AnandanCJankovicJ. Botulinum toxin in movement disorders: an update. Toxins (Basel). (2021) 13(1):42. 10.3390/toxins13010042
9.
MachadoAChienHFDegutiMMCançadoEAzevedoRSScaffMet alNeurological manifestations in Wilson’s disease: report of 119 cases. Mov Disord (2006) 21(12):2192–6. 10.1002/mds.21170
10.
ManegoldCHoffmannGFDegenIIkonomidouHKnustALaassMWet alAromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis (2009) 32(3):371–80. 10.1007/s10545-009-1076-1
11.
LeeJHKiCSKimDSChoJWParkKPKimS. Dopa-responsive dystonia with a novel initiation codon mutation in the GCH1 gene misdiagnosed as cerebral palsy. J Korean Med Sci (2011) 26(9):1244–6. 10.3346/jkms.2011.26.9.1244
12.
LizarragaKJFasanoA. Effects of deep brain stimulation on postural trunk deformities: a systematic review. Mov Disord Clin Pract (2019) 6(8):627–38. 10.1002/mdc3.12829
13.
HouJGGOndoWJankovicJ. Intrathecal baclofen for dystonia. Mov Disord (2001) 16(6):1201–2. 10.1002/mds.1215
14.
Gonzalez-LatapiPMarottaNMencacciNE. Emerging and converging molecular mechanisms in dystonia. J Neural Transm (2021) 128(4):483–98. 10.1007/s00702-020-02290-z
15.
CorpDTJoutsaJDarbyRRDelnoozCCSvan de WarrenburgBPCCookeDet alNetwork localization of cervical dystonia based on causal brain lesions. Brain (2019) 142(6):1660–74. 10.1093/brain/awz112
16.
LatorreARocchiLBhatiaKP. Delineating the electrophysiological signature of dystonia. Exp Brain Res (2020) 238(7–8):1685–92. 10.1007/s00221-020-05863-2
17.
JinnahHANeychevVHessEJ. The anatomical basis for dystonia: the motor network model. Tremor Other Hyperkinet Mov (N Y) (2017) 7:506. 10.7916/D8V69X3S
18.
SchirinziTSciamannaGMercuriNBPisaniA. Dystonia as a network disorder: a concept in evolution. Curr Opin Neurol (2018) 31(4):498–503. 10.1097/WCO.0000000000000580
19.
PrudenteCNHessEJJinnahHA. Dystonia as a network disorder: what is the role of the cerebellum?. Neuroscience (2014) 260:23–35. 10.1016/j.neuroscience.2013.11.062
20.
NeychevVKFanXMitevVIHessEJJinnahHA. The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain (2008) 131(9):2499–509. 10.1093/brain/awn168
21.
HanekampSSimonyanK. The large-scale structural connectome of task-specific focal dystonia. Hum Brain Mapp (2020) 41, 3253–65. 10.1002/hbm.25012
22.
BattistellaGSimonyanK. Top-down alteration of functional connectivity within the sensorimotor network in focal dystonia. Neurology (2019) 92(16):E1843–51. 10.1212/WNL.0000000000007317
23.
KorzeniewskiSJSlaughterJLenskiMHaakPPanethN. The complex aetiology of cerebral palsy. Nat Rev Neurol (2018) 14(9):528–43. 10.1038/s41582-018-0043-6
24.
PapadimitriouIDalivigkaZOutsikaCScarmeasNPonsR. Dystonia assessment in children with cerebral palsy and periventricular leukomalacia. Eur J Paediatr Neurol (2021) 32:8–15. 10.1016/j.ejpn.2021.03.005
25.
LumsdenDECroweBBasuAAminSDevlinADeAlwisYet alPharmacological management of abnormal tone and movement in cerebral palsy. Arch Dis Child (2019) 104(8):775–80. 10.1136/archdischild-2018-316309
26.
LevySEGiarelliELeeLCSchieveLAKirbyRSCunniffCet alAutism spectrum disorder and co-occurring developmental, psychiatric, and medical conditions among children in multiple populations of the United States. J Dev Behav Pediatr (2010) 31(4):267–75. 10.1097/DBP.0b013e3181d5d03b
27.
HanciFTüraySDilekMKabakuşN. Epilepsy and drug-resistant epilepsy in children with cerebral palsy: a retrospective observational study. Epilepsy Behav (2020) 112:107357. 10.1016/j.yebeh.2020.107357
28.
MeiCReillySReddihoughDMensahFPenningtonLMorganA. Language outcomes of children with cerebral palsy aged 5 years and 6 years: a population-based study. Dev Med Child Neurol (2016) 58(6):605–11. 10.1111/dmcn.12957
29.
ZhangJYOskouiMShevellM. A population-based study of communication impairment in cerebral palsy. J Child Neurol (2015) 30(3):277–84. 10.1177/0883073814538497
30.
AdegboyeDSterrALinJPOwenTJ. Theory of mind, emotional and social functioning, and motor severity in children and adolescents with dystonic cerebral palsy. Eur J Paediatr Neurol (2017) 21(3):549–56. 10.1016/j.ejpn.2017.01.013
31.
GrahamHKRosenbaumPPanethNDanBLinJPDamianoDLet alCerebral palsy. Nat Rev Dis Prim (2016) 2(1):15082–25. 10.1038/nrdp.2015.82
32.
McClellandVMLinJP. Sensorimotor integration in childhood dystonia and dystonic cerebral palsy—a developmental perspective. Front Neurol (2021) 12:668081–14. 10.3389/fneur.2021.668081
33.
BallabhPde VriesLS. White matter injury in infants with intraventricular haemorrhage: mechanisms and therapies. Nat Rev Neurol (2021) 17(4):199–214. 10.1038/s41582-020-00447-8
34.
LeanREHanRHSmyserTAKenleyJKShimonyJSRogersCEet alAltered neonatal white and gray matter microstructure is associated with neurodevelopmental impairments in very preterm infants with high-grade brain injury. Pediatr Res (2019) 86(3):365–74. 10.1038/s41390-019-0461-1
35.
VolpeJJ. Cerebellum of the premature infant: rapidly developing, vulnerable, clinically important. J Child Neurol (2009) 24(9):1085–104. 10.1177/0883073809338067
36.
MesserschmidtAPrayerDBruggerPCBoltshauserEZoderGSternisteWet alPreterm birth and disruptive cerebellar development: assessment of perinatal risk factors. Eur J Paediatr Neurol (2008) 12(6):455–60. 10.1016/j.ejpn.2007.11.003
37.
BaxMTydemanCFlodmarkO. Clinical and MRI correlates of cerebral palsy: the European cerebral palsy study. Jama (2006) 296(13):1602–8. 10.1001/jama.296.13.1602
38.
De VriesLSGroenendaalF. Patterns of neonatal hypoxic-ischaemic brain injury. Neuroradiology (2010) 52(6):555–66. 10.1007/s00234-010-0674-9
39.
KorzeniewskiSJBirbeckGDeLanoMCPotchenMJPanethN. A systematic review of neuroimaging for cerebral palsy. J Child Neurol (2008) 23(2):216–27. 10.1177/0883073807307983
40.
LimperopoulosCSoulJSGauvreauKHuppiPSWarfieldSKBassanHet alLate gestation cerebellar growth is rapid and impeded by premature birth. Pediatrics (2005) 115(3):688–95. 10.1542/peds.2004-1169
41.
CorpDTGreenwoodCJMorrison-HamJPullinenJMcDowallGMYoungerEFPet alClinical and structural findings in patients with lesion-induced dystonia: descriptive and quantitative analysis of published cases. Neurology (2022) 99:e1957–e1967. 10.1212/WNL.0000000000201042
42.
BattistellaGTermsarasabPRamdhaniRAFuertingerSSimonyanK. Isolated focal dystonia as a disorder of large-scale functional networks. Cereb Cortex (2017) 27(2): 1203–1215. 10.1093/cercor/bhv313
43.
TowsleyKShevellMIDagenaisL. Population-based study of neuroimaging findings in children with cerebral palsy. Eur J Paediatr Neurol (2011) 15:29–35. 10.1016/j.ejpn.2010.07.005
44.
ChintalapatiKMiaoHMathurANeilJAravamuthanBR. Objective and clinically feasible analysis of diffusion MRI data can help predict dystonia after neonatal brain injury. Pediatr Neurol (2021) 118(6–11):6–11. 10.1016/j.pediatrneurol.2020.11.011
45.
Laporta-hoyosOFioriSPannekKBallester-PlanéJLeivaDReidLBet alBrain lesion scores obtained using a simple semi-quantitative scale from MR imaging are associated with motor function, communication and cognition in dyskinetic cerebral palsy. Neuroimage Clin (2018) 19:892–900. 10.1016/j.nicl.2018.06.015
46.
ShevellMIDagenaisLHallNREPACQ CONSORTIUM*. The relationship of cerebral palsy subtype and functional motor impairment: a population-based study. Dev Med Child Neurol (2009) 51:872–7. 10.1111/j.1469-8749.2009.03269.x
47.
YoshidaSFariaAVOishiKKandaTYamoriYYoshidaNet alAnatomical characterization of athetotic and spastic cerebral palsy using an atlas-based analysis. J Magn Reson Imaging (2013) 38(2):288–98. 10.1002/jmri.23931
48.
Ballester-PlanéJSchmidtRLaporta-HoyosOJunquéCVázquezÉDelgadoIet alWhole-brain structural connectivity in dyskinetic cerebral palsy and its association with motor and cognitive function. Hum Brain Mapp (2017) 38(9):4594–612. 10.1002/hbm.23686
49.
WuRGaoYZhangHChenYTanFZengDet alMetabolic assessment of cerebral palsy with normal clinical MRI using 18F-FDG PET imaging: a preliminary report. Front Neurol (2022) 13:844911. 10.3389/fneur.2022.844911
50.
FoxMDGreiciusM. Clinical applications of resting state functional connectivity. Front Syst Neurosci (2010) 4:19. 10.3389/fnsys.2010.00019
51.
SmithaKAkhil RajaKArunKMRajeshPGThomasBKapilamoorthyTRet alResting state fMRI: a review on methods in resting state connectivity analysis and resting state networks. Neuroradiol J (2017) 30(4):305–17. 10.1177/1971400917697342
52.
QinYLiYSunBHeHPengRZhangTet alFunctional connectivity alterations in children with spastic and dyskinetic cerebral palsy. Neural Plast (2018) 2018:7058953. 10.1155/2018/7058953
53.
QinYSunBZhangHLiYZhangTLuoCet alAberrant interhemispheric functional organization in children with dyskinetic cerebral palsy. Biomed Res Int (2019) 2019:4362539. 10.1155/2019/4362539
54.
LeeRWPorettiACohenJSLeveyEGwynnHJohnstonMVet alA diagnostic approach for cerebral palsy in the genomic era. Neuromolecular Med (2014) 16(4):821–44. 10.1007/s12017-014-8331-9
55.
ChopraMGableDLLove-NicholsJTsaoARockowitzSSlizPet alMendelian etiologies identified with whole exome sequencing in cerebral palsy. Ann Clin Transl Neurol (2022) 9:193–205. 10.1002/acn3.51506
56.
CamargoCHFTeiveHAG. Evolution of the concept of dystonia. Arq Neuropsiquiatr (2014) 72(7):559–61. 10.1590/0004-282x20140056
57.
MarsdenCDObesoJAZarranzJJLangAE. The anatomical basis of symptomatic hemidystonia. Brain (1985) 4(108):463–83. 10.1093/brain/108.2.463
58.
PettigrewLCJankovicJ. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry (1985) 48(7):650–7. 10.1136/jnnp.48.7.650
59.
FoxMD. Mapping symptoms to brain networks with the human connectome. N Engl J Med (2018) 379(23):2237–45. 10.1056/NEJMra1706158
60.
BoesADPrasadSLiuHLiuQPascual-LeoneACavinessVSet alNetwork localization of neurological symptoms from focal brain lesions. Brain (2015) 138(10):3061–75. 10.1093/brain/awv228
61.
NeychevVKGrossRELehéricySHessEJJinnahHA. The functional neuroanatomy of dystonia. Neurobiol Dis (2011) 42(2):185–201. 10.1016/j.nbd.2011.01.026
62.
SimonyanK. Neuroimaging applications in dystonia. 1st ed. Amsterdam, Netherlands: Elsevier Inc. (2018).
63.
BucknerRLKrienenFMYeoBTT. Opportunities and limitations of intrinsic functional connectivity MRI. Nat Publ Gr (2013) 16(7):832–7. 10.1038/nn.3423
64.
ConteADefazioGMasciaMBelvisiDPantanoPBerardelliA. Advances in the pathophysiology of adult-onset focal dystonias: recent neurophysiological and neuroimaging evidence. F1000Research (2020) 9:67. 10.12688/f1000research.21029.2
65.
DelnoozCPasmanJBeckmannCFVan De WarrenburgBPC. Altered striatal and pallidal connectivity in cervical dystonia. Brain Struct Funct (2015) 220:513–23. 10.1007/s00429-013-0671-y
66.
BurciuRGHessCWCoombesSAOforiEShuklaPChungJWet alFunctional activity of the sensorimotor cortex and cerebellum relates to cervical dystonia symptoms. Hum Brain Mapp (2017) 38:4563–73. 10.1002/hbm.23684
67.
GiannìCPasquaGFerrazzanoGTommasinSDe BartoloMIPetsasNet alFocal dystonia: functional connectivity changes in cerebellar-basal ganglia-cortical circuit and preserved global functional architecture. Neurology (2022) 98(14):E1499–E1509. 10.1212/WNL.0000000000200022
68.
JinnahHAStillaRSinghSBuetefischCEvattMFactorSAet alA functional magnetic resonance imaging study of head movements in cervical dystonia. Front Neurol (2016) 7:1–13. 10.3389/fneur.2016.00201
69.
LøkkegaardAHerzDMHaagensenBNLorentzenAKEickhoffSBSiebnerHR. Altered sensorimotor activation patterns in idiopathic dystonia — an activation likelihood estimation meta-analysis of functional brain imaging studies. Hum Brain Mapp (2015) 37:547–57. 10.1002/hbm.23050
70.
SimonyanKBarkmeier-KraemerJBlitzerAHallettMHoudeJFJacobson KimberleyTet alLaryngeal dystonia: multidisciplinary update on terminology, pathophysiology, and research priorities. Neurology (2021) 96(21):989–1001. 10.1212/WNL.0000000000011922
71.
ChildsLRickertSMurryTBlitzerASulicaL. Patient perceptions of factors leading to spasmodic dysphonia: a combined clinical experience of 350 patients. Laryngoscope (2011) 121:2195–8. 10.1002/lary.22168
72.
TannerKRoyNMerrillRMKimberKSauderCHoutzDRet alRisk and protective factors for spasmodic dysphonia: a case-control investigation. J Voice (2011) 25(1):e35–e46. 10.1016/j.jvoice.2009.09.004
73.
StahlCMFruchtSJ. Focal task specific dystonia: a review and update. J Neurol (2017) 264(7):1536–41. 10.1007/s00415-016-8373-z
74.
ContiAMPullmanSFruchtSJ. The hand that has forgotten its cunning-lessons from musicians' hand dystonia. Hand Dystonia (2008) 23(10):1398–406. 10.1002/mds.21976
75.
LeeHYooSWKimJS. Task-specific dystonia in a professional billiard player. J Mov Disord (2022) 15(1):86–8. 10.14802/jmd.21055
76.
KimMSParkDGYoonJH. Blacksmith’s dystonia is another task-specific dystonia: from past to present. J Mov Disord (2022) 15(3):284–5. 10.14802/jmd.22037
77.
YooSLeeMKimJ. Stepping on the brakes ’ dystonic tremor: a new type of task-specific dystonic tremor of the lower extremity. Neurol Sci (2020) 41:477–9. 10.1007/s10072-019-04060-6
78.
LeeDKimJA. Call Cent Operator ’ s Dystonia. J Move Disord (2019) 12(1):57–9. 10.14802/jmd.18038
79.
OgasawaraIHatoriNRevankarGSKondaSUnoYNakanoTet alSymptom locus and symptom origin incongruity in runner’s dystonia - case study of an elite female runner. Front Hum Neurosci (2021) 15:809544. 10.3389/fnhum.2021.809544
80.
KimSKimH. Task-specific oromandibular dystonia in a telemarketer. J Mov Disord (2019) 12(2):125–7. 10.14802/jmd.18030
81.
LenkaAJankovicJ. Peripherally-induced movement disorders: an update. Tremor and Other Hyperkinetic Movements (2023) 13(8):8. 10.5334/tohm.758
82.
DomingoAYadavROzeliusLJ. Isolated dystonia: clinical and genetic updates. J Neural Transm (2021) 128(4):405–16. 10.1007/s00702-020-02268-x
83.
PutzelGGBattistellaGRumbachAFOzeliusLJSabuncuMRSimonyanK. Polygenic risk of spasmodic dysphonia is associated with vulnerable sensorimotor connectivity. Cereb Cortex (2016) 28:158–66. 10.1093/cercor/bhw363
84.
BianchiSFuertingerSHuddlestonHFruchtSJSimonyanK. Functional and structural neural bases of task specificity in isolated focal dystonia. Mov Disord (2019) 34(4):555–63. 10.1002/mds.27649
85.
DelmaireCVidailhetMElbazABourdainFBletonJPSanglaSet alStructural abnormalities in the cerebellum and sensorimotor circuit in writer’s cramp. Neurology (2007) 69(4):376–80. 10.1212/01.wnl.0000266591.49624.1a
86.
PoissonAKrackPThoboisSLoiraudCSerraGVialCet alHistory of the ‘geste antagoniste’ sign in cervical dystonia. J Neurol (2012) 259(8):1580–4. 10.1007/s00415-011-6380-7
87.
HallettM. Is dystonia a sensory disorder?Ann Neurol (1994) 38:139–40. 10.1002/ana.410380203
88.
StamelouMEdwardsMJHallettMBhatiaKP. The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain (2012) 135(6):1668–81. 10.1093/brain/awr224
89.
GhikaJRegliFGrowdonJH. Sensory symptoms in cranial dystonia: a potential role in the etiology?J Neurol Sci (1993) 116(2):142–7. 10.1016/0022-510x(93)90318-s
90.
KägiGKatschnigPFiorioMTinazziMRugeDRothwellJet alSensory tricks in primary cervical dystonia depend on visuotactile temporal discrimination. Mov Disord (2013) 28(3):356–61. 10.1002/mds.25305
91.
DeuschlGHeinenFKleedorferBWagnerMLückingCHPoeweW. Clinical and polymyographic investigation of spasmodic torticollis. J Neurol (1992) 239(1):9–15. 10.1007/BF00839204
92.
WisselJMüllerJEbersbachGPoeweW. Trick maneuvers in cervical dystonia: investigation of movement- and touch-related changes in polymyographic activity. Mov Disord (1999) 14(6):994–9. 10.1002/1531-8257(199911)14:6<994::aid-mds1013>3.0.co;2-k
93.
SarassoEAgostaFPiramideNBianchiFButeraCGattiRet alSensory trick phenomenon in cervical dystonia: a functional MRI study. J Neurol (2020) 267(4):1103–15. 10.1007/s00415-019-09683-5
94.
HokPHvizdošováLOtrubaPKaiserováMTrnečkováMTüdösZet alBotulinum toxin injection changes resting state cerebellar connectivity in cervical dystonia. Sci Rep (2021) 11(1):8322–11. 10.1038/s41598-021-87088-z
95.
JochimALiYGora-StahlbergGMantelTBerndtMCastropFet alAltered functional connectivity in blepharospasm/orofacial dystonia. Brain Behav (2018) 8(1):e00894–12. 10.1002/brb3.894
96.
LohAEliasGJBGermannJBoutetAGwunDYamamotoKet alNeural correlates of optimal deep brain stimulation for cervical dystonia. Ann Neurol (2022) 92(3):418–24. 10.1002/ana.26450
97.
FilipPJechRFečíkováAHavránkováPRůžičkaFMuellerKet alRestoration of functional network state towards more physiological condition as the correlate of clinical effects of pallidal deep brain stimulation in dystonia. Brain Stimul (2022) 15(5):1269–78. 10.1016/j.brs.2022.08.025
98.
MuraseNKajiRShimazuHKatayama-HirotaMIkedaAKoharaNet alAbnormal premovement gating of somatosensory input in writer’s cramp. Brain (2000) 123(9):1813–29. 10.1093/brain/123.9.1813
99.
Gomez-WongEMartiMJTolosaEVallis-SoléJ. Sensory modulation of the blink reflex in patients with blepharospasm. Arch Neurol (1998) 55(9):1233–7. 10.1001/archneur.55.9.1233
100.
JankovicJ. Botulinum toxin: state of the art. Mov Disord (2017) 32(8):1131–8. 10.1002/mds.27072
101.
MazzocchioRCaleoM. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist (2015) 21(1):44–61. 10.1177/1073858414524633
102.
RestaniLAntonucciFGianfranceschiLRossiCRossettoOCaleoM. Evidence for anterograde transport and transcytosis of Botulinum neurotoxin A (BoNT/A). J Neurosci (2011) 31(44):15650–9. 10.1523/JNEUROSCI.2618-11.2011
103.
CaiBBFrancisJBrinMFBroideRS. Botulinum neurotoxin type A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane following intramuscular toxin injection. Neuroscience (2017) 352:155–69. 10.1016/j.neuroscience.2017.03.049
104.
CurràABerardelliA. Do the unintended actions of botulinum toxin at distant sites have clinical implications?Neurology (2009) 72(12):1095–9. 10.1212/01.wnl.0000345010.98495.fc
105.
GiladiN. The mechanism of action of botulinum toxin type a in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci (1997) 152(2):132–5. 10.1016/s0022-510x(97)00151-2
106.
HokPVeverkaTHluštíkPNevrlýMKaňovskýP. The central effects of botulinum toxin in dystonia and spasticity. Toxins (Basel). (2021) 13(2):155. 10.3390/toxins13020155
107.
MantelTDreselCWelteMMeindlTJochimAZimmerCet alAltered sensory system activity and connectivity patterns in adductor spasmodic dysphonia. Sci Rep (2020) 10(1):10179–9. 10.1038/s41598-020-67295-w
108.
Ceballos-BaumannAOSheeanGPassinghamREMarsdenCDBrooksDJ. Botulinum toxin does not reverse the cortical dysfunction associated with writer’s cramp. A PET study. Brain (1997) 120(4):571–82. 10.1093/brain/120.4.571
109.
DreselCBayerFCastropFRimpauCZimmerCHaslingerB. Botulinum toxin modulates basal ganglia but not deficient somatosensory activation in orofacial dystonia. Mov Disord (2011) 26(8):1496–502. 10.1002/mds.23497
110.
OpavskýRHluštkPOtrubaPKaňovskýP. Somatosensory cortical activation in cervical dystonia and its modulation with botulinum toxin: an fMRI study. Int J Neurosci (2012) 122(1):45–52. 10.3109/00207454.2011.623807
111.
BrodoehlSWagnerFPrellTKlingnerCWitteOWGüntherA. Cause or effect: altered brain and network activity in cervical dystonia is partially normalized by botulinum toxin treatment. Neuroimage Clin (2019) 22:101792. 10.1016/j.nicl.2019.101792
112.
NevrlýMHluštíkPHokPOtrubaPTüdösZKaňovskýP. Changes in sensorimotor network activation after botulinum toxin type A injections in patients with cervical dystonia: a functional MRI study. Exp Brain Res (2018) 236(10):2627–37. 10.1007/s00221-018-5322-3
113.
HaslingerBErhardPDreselCCastropFRoettingerMCeballos-BaumannAO. ‘Silent event-related’ fMRI reveals reduced sensorimotor activation in laryngeal dystonia. Neurology (2005) 65(10):1562–9. 10.1212/01.wnl.0000184478.59063.db
114.
SuzukiYMizoguchiSKiyosawaMMochizukiMIshiwataKWakakuraMet alGlucose hypermetabolism in the thalamus of patients with essential blepharospasm. J Neurol (2007) 254(7):890–6. 10.1007/s00415-006-0468-5
115.
O’FlynnLCSimonyanK. Short- and long-term central action of botulinum neurotoxin treatment in laryngeal dystonia. Neurology (2022) 99:1178–90. 10.1212/wnl.0000000000200850
116.
PrudenteCNPardoCAXiaoJHanfeltJHessEJLedouxMSet alNeuropathology of cervical dystonia. Exp Neurol (2013) 241(1):95–104. 10.1016/j.expneurol.2012.11.019
117.
BucknerRLKrienenFMCastellanosADiazJYeoBTT. The organization of the human cerebellum estimated by intrinsic functional connectivity. J Neurophysiol (2011) 106(3):2322–45. 10.1152/jn.00339.2011
118.
StroudATischSDonkerB. Cerebellar cortex stimulation for acquired dystonia: a case report and review of its role in modern surgical practice. Stereotact Funct Neurosurg (2022) 100:321–30. 10.1159/000526072
119.
LozanoAMLipsmanNBergmanHBrownPChabardesSChangJWet alDeep brain stimulation: current challenges and future directions. Nat Rev Neurol (2019) 15(3):148–60. 10.1038/s41582-018-0128-2
120.
SuiYTianYKoWKDWangZJiaFHornAet alDeep brain stimulation initiative: toward innovative technology, new disease indications, and approaches to current and future clinical challenges in neuromodulation therapy. Front Neurol (2021) 11, 597451. 10.3389/fneur.2020.597451
121.
AumDJTierneyTS. Deep brain stimulation: foundations and future trends. Front Biosci Landmark Ed (2018) 23(1):162–82. 10.2741/4586
122.
DeebWMalatyI. Deep brain stimulation for tourette syndrome: potential role in the pediatric population. J Child Neurol (2020) 35(2):155–65. 10.1177/0883073819872620
123.
DoughertyDD. Deep brain stimulation: clinical applications. Psychiatr Clin North Am (2018) 41(3):385–94. 10.1016/j.psc.2018.04.004
124.
KupschABeneckeRMüllerJTrottenbergTSchneiderGHPoeweWet alPallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med (2006) 355(19):1978–90. 10.1056/NEJMoa063618
125.
VolkmannJMuellerJDeuschlGKühnAAKraussJKPoeweWet alPallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol (2014) 13(9):875–84. 10.1016/S1474-4422(14)70143-7
126.
JinnahHAAltermanRKleinCKraussJKMoroEVidailhetMet alDeep brain stimulation for dystonia: a novel perspective on the value of genetic testing. J Neural Transm (2017) 124(4):417–30. 10.1007/s00702-016-1656-9
127.
HøckANJensenSRSvaerkeKWBrennumJJespersenBBergdalOet alA randomised double-blind controlled study of deep brain stimulation for dystonia in STN or GPi - a long term follow-up after up to 15 years. Parkinsonism Relat Disord (2022) 96:74–9. 10.1016/j.parkreldis.2022.02.001
128.
MalattCTagliatiM. Long-term outcomes of deep brain stimulation for pediatric dystonia. Pediatr Neurosurg (2022) 57(4):225–37. 10.1159/000524577
129.
BrüggemannNKühnASchneiderSAKammCWoltersAKrausePet alShort- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. Neurology (2015) 84(9):895–903. 10.1212/WNL.0000000000001312
130.
KimARChangJWChangWSParkESChoSR. Two-year outcomes of deep brain stimulation in adults with cerebral palsy. Ann Rehabil Med (2014) 38(2):209–17. 10.5535/arm.2014.38.2.209
131.
TischSKumarKR. Pallidal deep brain stimulation for monogenic dystonia: the effect of gene on outcome. Front Neurol (2021) 11:630391. 10.3389/fneur.2020.630391
132.
AravamuthanBRWaughJLStoneSS. Deep brain stimulation for monogenic dystonia. Curr Opin Pediatr (2017) 29(6):691–6. 10.1097/MOP.0000000000000548
133.
KoyAHellmichMPaulsKAMMarksWLinJPFrickeOet alEffects of deep brain stimulation in dyskinetic cerebral palsy: a meta-analysis. Mov Disord (2013) 28(5):647–54. 10.1002/mds.25339
134.
EliaAEBagellaCFFerréFZorziGCalandrellaDRomitoLM. Deep brain stimulation for dystonia due to cerebral palsy: a review. Eur J Paediatr Neurol (2018) 22(2):308–15. 10.1016/j.ejpn.2017.12.002
135.
SangerTD. Deep brain stimulation for cerebral palsy: where are we now?Dev Med Child Neurol (2020) 62(1):28–33. 10.1111/dmcn.14295
136.
BohnEGorenKSwitzerLFalck-YtterYFehlingsD. Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis. Dev Med Child Neurol (2021) 63(9):1038–50. 10.1111/dmcn.14874
137.
LucianoMSRobichaux-ViehoeverADodenhoffKAGittingsMLViserACRacineCAet alThalamic deep brain stimulation for acquired dystonia in children and young adults: a phase 1 clinical trial. J Neurosurg Pediatr (2021) 27(2):203–12. 10.3171/2020.7.PEDS20348
138.
WolfMEBlahakCSaryyevaASchraderCKraussJK. Deep brain stimulation for dystonia-choreoathetosis in cerebral palsy: pallidal versus thalamic stimulation. Park Relat Disord (2019) 63:209–12. 10.1016/j.parkreldis.2019.01.029
139.
MorigakiRMiyamotoRMatsudaTMiyakeKYamamotoNTakagiY. Dystonia and cerebellum: from bench to bedside. Life (2021) 11(8):776. 10.3390/life11080776
140.
NicholsonCLCoubesPPoulenG. Dentate nucleus as target for deep brain stimulation in dystono-dyskinetic syndromes. Neurochirurgie (2020) 66(4):258–65. 10.1016/j.neuchi.2020.04.132
141.
HorisawaSAraiTSuzukiNKawamataTTairaT. The striking effects of deep cerebellar stimulation on generalized fixed dystonia: case report. J Neurosurg (2020) 132(3):712–6. 10.3171/2018.11.JNS182180
142.
LinSZhangCLiHWangYWuYWangTet alHigh frequency deep brain stimulation of superior cerebellar peduncles in a patient with cerebral palsy. Tremor and Other Hyperkinetic Movements (2020) 10(1):1–11. 10.5334/tohm.551
143.
SokalPRudasMHaratMSzylbergŁZielińskiP. Deep anterior cerebellar stimulation reduces symptoms of secondary dystonia in patients with cerebral palsy treated due to spasticity. Clin Neurol Neurosurg (2015) 135:62–8. 10.1016/j.clineuro.2015.05.017
144.
CalderonDPFremontRKraenzlinFKhodakhahK. The neural substrates of rapid-onset dystonia-parkinsonism. Nat Neurosci (2011) 14(3):357–65. 10.1038/nn.2753
145.
PizoliCEJinnahHABillingsleyMLHessEJ. Abnormal cerebellar signaling induces dystonia in mice. J Neurosci (2002) 22(17):7825–33. 10.1523/JNEUROSCI.22-17-07825.2002
146.
WangT-CNgampramuanSKotchabhakdiN. Tiagabine treatment in kainic acid induced cerebellar lesion of dystonia rat model. EXCLI J (2016) 15:716–29. 10.17179/excli2016-482
147.
WhiteJJSillitoeRV. Genetic silencing of olivocerebellar synapses causes dystonia-like behaviour in mice. Nat Commun (2017) 8:14912. 10.1038/ncomms14912
148.
van der HeijdenMELackeyEPPerezRIșleyenFSBrownAMDonofrioSGet alMaturation of Purkinje cell firing properties relies on neurogenesis of excitatory neurons. Elife (2021) 10:e68045–37. 10.7554/eLife.68045
149.
BrownAMvan der HeijdenMEJinnahHASillitoeRV. Cerebellar dysfunction as a source of dystonic phenotypes in mice. Cerebellum (2022) 22:719–29. 10.1007/s12311-022-01441-0
150.
LedouxMSLordenJF. Abnormal spontaneous and harmaline-stimulated Purkinje cell activity in the awake genetically dystonic rat. Exp Brain Res (2002) 145(4):457–67. 10.1007/s00221-002-1127-4
151.
FanXDonsanteYJinnahHAHessEJ. Dopamine receptor agonist treatment of idiopathic dystonia: a reappraisal in humans and mice. J Pharmacol Exp Ther (2018) 365(1):20–6. 10.1124/jpet.117.246348
152.
FremontRPaola CalderonDMalekiSKhodakhahK. Abnormal high-frequency burst firing of cerebellar neurons in rapid-onset dystonia-parkinsonism. J Neurosci (2014) 34(35):11723–32. 10.1523/JNEUROSCI.1409-14.2014
153.
Georgescu MargarintELGeorgescuIAZahiuCDMTirleaSAŞteopoaieARZǎgreanLet alReduced interhemispheric coherence in cerebellar kainic acid-induced lateralized dystonia. Front Neurol (2020) 11, 580540–13. 10.3389/fneur.2020.580540
154.
MargarintELGGeorgescuIAZahiuCDMȘteopoaieARTirleaSAPopDet alReduced interhemispheric coherence after cerebellar vermis output perturbation. Brain Sci (2020) 10(9):1–16. 10.3390/brainsci10090621
155.
RaikeRSPizoliCEWeiszCvan den MaagdenbergAMJMJinnahHAHessEJ. Limited regional cerebellar dysfunction induces focal dystonia in mice. Neurobiol Dis (2013) 49(1):200–10. 10.1016/j.nbd.2012.07.019
156.
FernagutPODiguetEStefanovaNBiranMWenningGKCanioniPet alSubacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience (2002) 114(4):1005–17. 10.1016/s0306-4522(02)00205-1
157.
AïssaHBSalaRWGeorgescu MargarintELFronteraJLVaraniAPMenardyFet alFunctional abnormalities in the cerebellothalamic pathways in a mouse model of DYT25 dystonia. Elife (2022) 11. 10.7554/elife.79135
158.
KernodleKBakerianAMCropseyADauerWTLeventhalDK. A dystonia mouse model with motor and sequencing deficits paralleling human disease. Behav Brain Res (2022) 426:113844. 10.1016/j.bbr.2022.113844
159.
Van Der HeijdenMEGillJSRey HipolitoAGSalazar LeonLESillitoeRV. Quantification of behavioral deficits in developing mice with dystonic behaviors. Dystonia (2022) 1:10494–17. 10.3389/dyst.2022.10494
160.
LeDouxMSHurstDCLordenJF. Single-unit activity of cerebellar nuclear cells in the awake genetically dystonic rat. Neuroscience (1998) 86(2):533–45. 10.1016/s0306-4522(98)00007-4
161.
Salazar LeonLESillitoeRV. Potential interactions between cerebellar dysfunction and sleep disturbances in dystonia. Dystonia (2022) 1:10691–13. 10.3389/dyst.2022.10691
162.
Salazar LeonLESillitoeRV. Disrupted sleep in dystonia depends on cerebellar function but not motor symptoms in mice (2023). bioRxiv, Available From: https://www.biorxiv.org/content/biorxiv/early/2023/02/10/2023.02.09.527916.full.pdf.
163.
KuyperDJParraVAertsSOkunMSKlugerBM. Nonmotor manifestations of dystonia: a systematic review. Mov Disord (2011) 26(7):1206–17. 10.1002/mds.23709
164.
NovarettiNCunhaALNBezerraTCPereiraMAPDe OliveiraDSBritoMMCMet alThe prevalence and correlation of non-motor symptoms in adult patients with idiopathic focal or segmental dystonia. Tremor and Other Hyperkinetic Movements (2019) 9:596–7. 10.5334/tohm.466
Summary
Keywords
dystonia, cerebellum, dyskinetic cerebral palsy, dystonia network, network disorder
Citation
Gill JS, Nguyen MX, Hull M, van der Heijden ME, Nguyen K, Thomas SP and Sillitoe RV (2023) Function and dysfunction of the dystonia network: an exploration of neural circuits that underlie the acquired and isolated dystonias. Dystonia 2:11805. doi: 10.3389/dyst.2023.11805
Received
14 July 2023
Accepted
27 November 2023
Published
13 December 2023
Volume
2 - 2023
Edited by
Aasef Shaikh, Case Western Reserve University, United States
Updates

Check for updates
Copyright
© 2023 Gill, Nguyen, Hull, van der Heijden, Nguyen, Thomas and Sillitoe.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Roy V. Sillitoe, sillitoe@bcm.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.